Study of cord blood natural killer cell suppressor activity

European Journal of Haematology

Volumn 66, Issue 4, 2001, Pages 215-220

  El Marsafy, Sanaa ^a,d   Dosquet, C ^b   Coudert, M C ^b   Bensussan, A ^c   Carosella, E ^d   Gluckman, E ^a  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b U de Thérapie Cellulaire   (France)

^c INSERM   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Cord blood; Graft versus host disease; Natural killer cells

Indexed keywords

MONOCLONAL ANTIBODY; THYMIDINE; TRITIUM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD BLOOD;

ADULT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FETAL BLOOD; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035005215     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.066004215.x     Document Type: Article

References (45)

1. 1. WAGNER JE, KERMAN N, STEINBACH AD, BROXMEYER HE, GLUCKMAN E. Allogeneic sibling umbilical cord transplantation in children with malignant and non-malignant disease. Lancet 1995;346:214-217.
2. 2. ROCHA V, WAGNER JE, SOBOCINSKI KA, et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 2000;342:1846-1854.
3. 3. KURTZBERG J, LAUGHKIN M, GRAHAM ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335: 157-163.
4. 4. WAGNER JE. Umbilical cord blood transplantation: overview of the clinical experience. Blood cells 1994;20:227-232.
5. 5. RISDON G, GADDY J, BROXMEYER HE. Allogeneic response of human umbilical cord blood. Blood cells 1994;20:566-572.
6. 6. RONCAROLO M-G, BIGLE M, CIUTI E, MARTINO S, TOVO P-A. Immune responses by cord blood cells. Blood Cells 1994;20: 573-586.
7. 7. DEACOCK SJ, SCHWARER PA, BRIDGE J, BATCHELOR JR, GOLDMAN JM, LECHLER RI. Evidence that umbilical cord blood contains a higher frequency of HLA class II-specific alloreactive T cells than adult peripheral blood. Transplantation 1992;53:1128-1134.
8. 8. RISDON G, GADDY J, HORIE M, BROXMEYER HE. Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. Proc Natl Acad Sci USA 1995;92:2413-2417.
9. 9. PORCU P, GADDY J, BROXMEYER HE. Allogantigen-induced unresponsiveness in cord blood T lymphocytes is associated with defective activation of Ras. Proc Natl Acad Sci USA 1998;95:4538-4543.
10. 10. COHEN SBA, DOMINIGUEZ E, LOWDELL M, MADRIGAL JA. The immunological properties of cord blood: overview of current research presented at the 2nd EUROCORD Workshop. Bone Marrow Transplant 1998;22 (Suppl I): S22-S25.
11. 11. ASAI O, LONGO DL, TIAN ZG, et al. Suppression of graft-versus-host disease and amplification of graft versus-tumor effect by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998;9:1835-1842.
12. 12. ASIEDU C, MENG Y, WANG W, et al. Immunoregulatory role of CD8α in the veto effect. Transplantation 1999;67:372-380.
13. 13. WEISS L, SLAVIN S. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999;23: 1139-1143.
14. 14. BARAO I, ASCENCAO JL. Human natural killer cells. Arch Immunol Ther Exp 1998;46:213-229.
15. 15. KOS FJ. Regulation of adaptive immunity by natural killer cells. Immunol Res 1998;17:303-312.
16. 16. ROSSI AR, PERICLE F, RASHLEGH S, JANIEC J, DJEU JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994;83:1323-1328.
17. 17. TRINCHIERI G. Biology and natural killer cells. Adv Immunol 1989;47:187-376.
18. 18. CHE S, HUSTON DP. Natural killer cell suppression of IgM production. Nat Immun 1994;13:258-269.
19. 19. BOSSE D, ADES E. Suppression of human immunoglobulin synthesis by interleukin 4 in tandem with interleukin-2 through large granular lymphocytes. Pathobiology 1991;59:391-395.
20. 20. AZUMA E, KAPLAN J. Role of lymphokine activated killer (LAK) cells as mediators of veto and natural suppression. J Immunol 1988;141:2601-2606.
21. 21. UBERTI J, MARTILLOTI F, CHOU T-H, KAPLAN J. Human LAK cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation. Blood 1992;79:261-268.
22. 22. MILLS KC, GROSS TG, VARNEY ML, et al. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transplant 1996;18:53-61.
23. 23. BECK R, LAM-PO-TANG PR. Comparison of cord blood and adult blood lymphocyte normal ranges: a possible explanation for decreased severity of graft versus host disease after cord blood transplantation. Immunol Cell Biol 1994;72:440-444.
24. 24. BENSUSSAN A, GLUCKMAN E, EL MARSAFY S, et al. BY55+ monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. Proc Natl Acad Sci 1994;91:9136-9140.
25. 25. D'ARENA G, MUSTO P, CASCAVILLA N, DI GIORGIO G, FUSILLI S, ZENDOLI CM. Flow cytometric characterization of human umbilical cord lymphocytes: immunophenotypic features. Haematologica 1998;83:197-203.
26. - cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 1997;180:132-142.
27. 27. UMEMOTO M, AZUMA E, HIRAYAMA M, et al. Two cytotoic pathways of natural killer cells in human cord blood: implications in cord blood transplantation. 1997;98:1037-1040.
28. 28. DOMINGUEZ E, MADRIGA JA, LAYRISSE Z, COHEN SB. Fetal natural killer cell function is suppressed. Immunol 1998;94:109-114.
29. 29. MÏZA H, LECA G, MANSUR I-G, SCHIAVON V, BOUMSELL L, BENSUSSSAN A. A novel 80-KDa cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 1994;178:1121-1126.
30. + T cells into the S phase of the cell cycle without interfering with early activation signals. Transplantation 1996;62:1136-1143.
31. 31. SHALABY MR, ESPEVIK T, RICE GC, et al. The involvement of human tumour necrosis factors-α in the mixed lymphcyte reaction. J Immunol 1988;141:499-503.
32. 32. FERRARA JLM, DEEG HJ. Mechanisms of disease: graft-versus-host disease. N Engl J Med 1991;324:667-674.
33. 33. FACON T, JOUET JP, NOEL-WALTER MP, BLOGET F, BAUTERS F, JANIN A. Involvement of TNF-α secreting macrophages in lethal forms human graft-versus-host disease. Bone Marrow Transplant 1997;20:511-515.
34. 34. FERRARA JLM. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant 1998;21 (Suppl. 3): S13-S15.
35. 35. JADUS MR, WEPSIC HT. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992;10:1-14.
36. 36. NEIDERWEISER D, HEROLD M, WOLOSZUK W, AULITZKY W, MEISTER B. Endogenous IFN-gamma during human bone marrow transplantation. Transplantation 1990;50:620-626.
37. 37. COOKE KR, HILL GR, CRAWFORD JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998;102:1882-1891.
38. 38. ROBINET E, BRANELLEC D, TERMIJTELEN AM, BLAY JY, GA F, CHOUAIB S. Evidence for tumor necrosis factor-α involvment in the optimal induction of class I allospecific cytotoxicity T cells. J Immunol 1990;144:4555-4561.
39. 39. GLIMCHER LH, KARA CJ. Sequences and factors. A guide to MHC class II transcription. Ann Rev Immunol 1992;10:13-19.
40. 40. JASINISKI M, WIECKIEWICZ J, RUGGIERO I, NOWOROLSKA P, ZEMBALA M. Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor. J Clin Immunol 1995;15:185-193.
41. 41. HOLLER E, KOLB HJ, HEINTERMEIER-KNABE R. Role of tumour necrosis factor alpha in graft-versus-host disease. Transplant Proc 1993;25:1234-1239.
42. 42. KASAHARA T, DJEU JY, DOUGHERTY SF, OPPENHEIM JJ. Capacity of human large granular lymphocytes (LGL) to produce multiple interleukines: interleukin-2, interferon and colony stimulating factor. J Immunol 1983;131:2379-2385.
43. 43. MURPHY WJ, KELLER JR, HARRISON CL, YOUNG HA, LONGO DL. Interleukin-2 activated natural killler cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 1991;80:670-677.
44. 44. ELLISON CA, HAYGLASS KT, FISHER JM, RECTOR ES, MACDONALD GC, GARTENER JG. Depletion of NK cells from the graft reduces interferon-gamma levels and lipopolysaccharide-induced tumor necrosis factor-alpha release in F1 hybrid mice with acute graft-versus-host disease. Transplantation 1998;66:284-294.
45. 45. OTTENHOF THM, WALFORD C, NISHMURA Y, REDDY NBB, SASAZUKI T. HLA-DQ molecules and the control of Mycobacterium leprae-speciflc T cell nonresponsiveness in lepromatous leprosy patients. Eur J Immunol 1990;20:2347-2350.